Syntara Limited has released a press release.
PXS Announces First Results in Bone Marrow Cancer Trial
Filed with ASX · · 3 pages · English
6ix is checking which company filed this.
Earlier from Syntara
- Quarterly Activity Report
- Appendix 4C - quarterly
- Sale of Russian Distribution Rights
- First Patient Enrolled - Clinical Trial for Cancer Treatment
- Pharmaxis Exports CF Drug to US - US$3 Million Milestone
Later from Syntara
- PXS Sells Australian Distribution Rights for A$2m
- PXS Drug Decreases Tumour Burden in Liver Cancer Model
- PXS Grants Exclusive Option to Develop High Payload Inhaler
- Pharmaxis Treatment to Prevent Wound and Burns Scars Clears
- PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara